HeraMED Limited (ASX:HMD)

HeraMED Statistics

Total Valuation

HeraMED has a market cap or net worth of AUD 41.72 million. The enterprise value is 40.77 million.

Market Cap	41.72M
Enterprise Value	40.77M

Important Dates

The next estimated earnings date is Friday, February 27, 2026.

Earnings Date	Feb 27, 2026
Ex-Dividend Date	n/a

Share Statistics

HeraMED has 1.04 billion shares outstanding. The number of shares has increased by 145.72% in one year.

Current Share Class	1.04B
Shares Outstanding	1.04B
Shares Change (YoY)	+145.72%
Shares Change (QoQ)	+25.03%
Owned by Insiders (%)	8.93%
Owned by Institutions (%)	7.03%
Float	836.41M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	129.20
PB Ratio	72.43
P/TBV Ratio	72.43
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-8.99
EV / Sales	126.24
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-10.21

Financial Position

The company has a current ratio of 3.04

Current Ratio	3.04
Quick Ratio	2.33
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-2,325.16

Financial Efficiency

Return on equity (ROE) is -518.37% and return on invested capital (ROIC) is -253.83%.

Return on Equity (ROE)	-518.37%
Return on Assets (ROA)	-105.38%
Return on Invested Capital (ROIC)	-253.83%
Return on Capital Employed (ROCE)	-370.65%
Weighted Average Cost of Capital (WACC)	8.27%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.14
Inventory Turnover	0.38

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +135.29% in the last 52 weeks. The beta is 0.73, so HeraMED's price volatility has been lower than the market average.

Beta (5Y)	0.73
52-Week Price Change	+135.29%
50-Day Moving Average	0.04
200-Day Moving Average	0.03
Relative Strength Index (RSI)	48.28
Average Volume (20 Days)	819,981

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, HeraMED had revenue of AUD 322,933 and -4.53 million in losses. Loss per share was -0.01.

Revenue	322,933
Gross Profit	189,574
Operating Income	-3.94M
Pretax Income	-4.53M
Net Income	-4.53M
EBITDA	-4.06M
EBIT	-3.94M
Loss Per Share	-0.01

Balance Sheet

The company has 954,447 in cash and n/a in debt, with a net cash position of 954,447 or 0.00 per share.

Cash & Cash Equivalents	954,447
Total Debt	n/a
Net Cash	954,447
Net Cash Per Share	0.00
Equity (Book Value)	576,044
Book Value Per Share	0.00
Working Capital	1.04M

Cash Flow

In the last 12 months, operating cash flow was -4.05 million and capital expenditures 58,770, giving a free cash flow of -3.99 million.

Operating Cash Flow	-4.05M
Capital Expenditures	58,770
Free Cash Flow	-3.99M
FCF Per Share	-0.00

Margins

Gross Margin	58.70%
Operating Margin	-1,221.14%
Pretax Margin	-1,404.04%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

HeraMED does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-145.72%
Shareholder Yield	-145.72%
Earnings Yield	-10.87%
FCF Yield	-9.57%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

HeraMED has an Altman Z-Score of -36.49 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-36.49
Piotroski F-Score	2